TAO Synergies (TAOX) Long-Term Investments (2023 - 2026)

TAO Synergies' (TAOX) quarterly Long-Term Investments came in at $478824.0 in Q2 2026, down 39.97% quarter-over-quarter from $797694.0 in Q1 2026.

Analysis

TAO Synergies (TAOX) Long-Term Investments (2023 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Long-Term Investments for 4 consecutive years, with $478824.0 the latest figure, recorded in Q2 2026.

For the quarter ending Q2 2026, Long-Term Investments changed N/A year-over-year to $478824.0; the trailing twelve-month figure through Jun 2026 stood at $478824.0 (changed N/A YoY), and the FY2025 full-year result was $446954.0, changed N/A from the prior year.
Long-Term Investments eased to $478824.0 in Q2 2026 per TAOX's latest filing, from $797694.0 in the prior quarter.
Across five years, Long-Term Investments topped out at $797694.0 in Q1 2026 and bottomed at $446954.0 in Q4 2025.
Historically, Long-Term Investments has averaged $559365.0 across 4 years, with a median of $543952.0 in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Amgen	210.97 Bn	196.98 Bn	7.24 Bn	-
2	Gilead Sciences	180.98 Bn	177.80 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	132.09 Bn	124.24 Bn	2.84 Bn	5.79 Bn
4	Regeneron Pharmaceuticals	82.56 Bn	74.57 Bn	3.93 Bn	9.83 Bn
5	Argenx Se	61.71 Bn	56.53 Bn	1.37 Bn	-4.00 Mn
6	Moderna	54.60 Bn	49.46 Bn	52.00 Mn	1.77 Bn
7	Alnylam Pharmaceuticals	34.02 Bn	30.71 Bn	992.69 Mn	22.17 Mn
8	Biogen	31.25 Bn	29.97 Bn	1.96 Bn	-
9	Roivant Sciences	29.76 Bn	29.76 Bn	1.16 Mn	-
10	TAO Synergies	30.86 Mn	30.86 Mn	-	478,824.00

Historic Data

Download Data